Top

10-03-2025 | Type 2 Diabetes | Review

Clonal haematopoiesis of indeterminate potential: an emerging risk factor for type 2 diabetes and related complications

Authors: María A. Zuriaga, José J. Fuster

Abstract

The accumulation of acquired somatic mutations is a natural consequence of ageing, but the pathophysiological implications of these mutations beyond cancer are only beginning to be understood. Most somatic mutations are functionally neutral, but a few may confer a competitive advantage to a stem cell, driving its clonal expansion. When such a mutation arises in haematopoietic stem cells, it leads to clonal haematopoiesis, in which a significant proportion of blood cells originate from the mutant stem cell and share the same mutation. Clonal haematopoiesis of indeterminate potential (CHIP), a specific subset of clonal haematopoiesis driven by myeloid leukaemia-related somatic mutations, has been linked to a higher risk of various age-related conditions, particularly CVD, by exacerbating inflammatory responses. Emerging evidence suggests that CHIP may also contribute to the pathogenesis of type 2 diabetes and some of its complications. This review synthesises current knowledge on CHIP and its potential as a novel risk factor for type 2 diabetes, highlighting the need for further research to clarify this relationship and to explore its potential value in developing personalised preventive care strategies for type 2 diabetes and related conditions.

Graphical Abstract

Available only for authorised users

Cole JB, Florez JC (2020) Genetics of diabetes mellitus and diabetes complications. Nat Rev Nephrol 16(7):377–390. https://doi.org/10.1038/s41581-020-0278-5CrossRefPubMedPubMedCentral

Pillon NJ, Loos RJF, Marshall SM, Zierath JR (2021) Metabolic consequences of obesity and type 2 diabetes: Balancing genes and environment for personalized care. Cell 184(6):1530–1544. https://doi.org/10.1016/j.cell.2021.02.012CrossRefPubMedPubMedCentral

Mustjoki S, Young NS (2021) Somatic mutations in “Benign” disease. N Engl J Med 384(21):2039–2052. https://doi.org/10.1056/NEJMra2101920CrossRefPubMed

Weeks LD, Ebert BL (2023) Causes and consequences of clonal hematopoiesis. Blood 142(26):2235–2246. https://doi.org/10.1182/blood.2023022222CrossRefPubMedPubMedCentral

Petrone G, Turker I, Natarajan P, Bolton KL (2024) Clinical and therapeutic implications of clonal hematopoiesis. Annu Rev Genomics Hum Genet 25(1):329–351. https://doi.org/10.1146/annurev-genom-120722-100409CrossRefPubMed

Lee-Six H, Obro NF, Shepherd MS et al (2018) Population dynamics of normal human blood inferred from somatic mutations. Nature 561(7724):473–478. https://doi.org/10.1038/s41586-018-0497-0CrossRefPubMedPubMedCentral

Osorio FG, Rosendahl Huber A, Oka R et al (2018) Somatic mutations reveal lineage relationships and age-related mutagenesis in human hematopoiesis. Cell Rep 25(9):2308-2316 e2304. https://doi.org/10.1016/j.celrep.2018.11.014CrossRefPubMedPubMedCentral

Welch JS, Ley TJ, Link DC et al (2012) The origin and evolution of mutations in acute myeloid leukemia. Cell 150(2):264–278. https://doi.org/10.1016/j.cell.2012.06.023CrossRefPubMedPubMedCentral

Steensma DP, Bejar R, Jaiswal S et al (2015) Clonal hematopoiesis of indeterminate potential and its distinction from myelodysplastic syndromes. Blood 126(1):9–16. https://doi.org/10.1182/blood-2015-03-631747CrossRefPubMedPubMedCentral

10.

Niroula A, Sekar A, Murakami MA et al (2021) Distinction of lymphoid and myeloid clonal hematopoiesis. Nat Med 27(11):1921–1927. https://doi.org/10.1038/s41591-021-01521-4CrossRefPubMedPubMedCentral

11.

Williams N, Lee J, Mitchell E et al (2022) Life histories of myeloproliferative neoplasms inferred from phylogenies. Nature 602(7895):162–168. https://doi.org/10.1038/s41586-021-04312-6CrossRefPubMed

12.

Jaiswal S, Fontanillas P, Flannick J et al (2014) Age-related clonal hematopoiesis associated with adverse outcomes. N Engl J Med 371(26):2488–2498. https://doi.org/10.1056/NEJMoa1408617CrossRefPubMedPubMedCentral

13.

Bick AG, Weinstock JS, Nandakumar SK et al (2020) Inherited causes of clonal haematopoiesis in 97,691 whole genomes. Nature 586(7831):763–768. https://doi.org/10.1038/s41586-020-2819-2CrossRefPubMedPubMedCentral

14.

Kessler MD, Damask A, O’Keeffe S et al (2022) Common and rare variant associations with clonal haematopoiesis phenotypes. Nature 612(7939):301–309. https://doi.org/10.1038/s41586-022-05448-9CrossRefPubMedPubMedCentral

15.

Diez-Diez M, Ramos-Neble BL, de la Barrera J et al (2024) Unidirectional association of clonal hematopoiesis with atherosclerosis development. Nat Med 30(10):2857–2866. https://doi.org/10.1038/s41591-024-03213-1CrossRefPubMedPubMedCentral

16.

Buscarlet M, Provost S, Zada YF et al (2017) DNMT3A and TET2 dominate clonal hematopoiesis and demonstrate benign phenotypes and different genetic predispositions. Blood 130(6):753–762. https://doi.org/10.1182/blood-2017-04-777029CrossRefPubMed

17.

Bonnefond A, Skrobek B, Lobbens S et al (2013) Association between large detectable clonal mosaicism and type 2 diabetes with vascular complications. Nat Genet 45(9):1040–1043. https://doi.org/10.1038/ng.2700CrossRefPubMed

18.

Lin SH, Brown DW, Rose B et al (2021) Incident disease associations with mosaic chromosomal alterations on autosomes, X and Y chromosomes: insights from a phenome-wide association study in the UK Biobank. Cell Biosci 11(1):143. https://doi.org/10.1186/s13578-021-00651-zCrossRefPubMedPubMedCentral

19.

Kar SP, Quiros PM, Gu M et al (2022) Genome-wide analyses of 200,453 individuals yield new insights into the causes and consequences of clonal hematopoiesis. Nat Genet 54(8):1155–1166. https://doi.org/10.1038/s41588-022-01121-zCrossRefPubMedPubMedCentral

20.

Tobias DK, Manning AK, Wessel J et al (2023) Clonal Hematopoiesis of Indeterminate Potential (CHIP) and incident type 2 diabetes risk. Diabetes Care 46(11):1978–1985. https://doi.org/10.2337/dc23-0805CrossRefPubMedPubMedCentral

21.

Pascual-Figal DA, Bayes-Genis A, Diez-Diez M et al (2021) Clonal hematopoiesis and risk of progression of heart failure with reduced left ventricular ejection fraction. J Am Coll Cardiol 77(14):1747–1759. https://doi.org/10.1016/j.jacc.2021.02.028CrossRefPubMed

22.

Assmus B, Cremer S, Kirschbaum K et al (2021) Clonal haematopoiesis in chronic ischaemic heart failure: prognostic role of clone size for DNMT3A- and TET2-driver gene mutations. Eur Heart J 42(3):257–265. https://doi.org/10.1093/eurheartj/ehaa845CrossRefPubMed

23.

Zhao K, Shen X, Liu H et al (2024) Somatic and germline variants and coronary heart disease in a Chinese population. JAMA Cardiol 9(3):233–242. https://doi.org/10.1001/jamacardio.2023.5095CrossRefPubMedPubMedCentral

24.

Vlasschaert C, Heimlich JB, Rauh MJ, Natarajan P, Bick AG (2023) Interleukin-6 receptor polymorphism attenuates clonal hematopoiesis-mediated coronary artery disease risk among 451 180 individuals in the UK biobank. Circulation 147(4):358–360. https://doi.org/10.1161/CIRCULATIONAHA.122.062126CrossRefPubMedPubMedCentral

25.

Kim MJ, Song H, Koh Y et al (2023) Clonal hematopoiesis as a novel risk factor for type 2 diabetes mellitus in patients with hypercholesterolemia. Front Public Health 11:1181879. https://doi.org/10.3389/fpubh.2023.1181879CrossRefPubMedPubMedCentral

26.

Fuster JJ, Zuriaga MA, Zorita V et al (2020) TET2-loss-of-function-driven clonal hematopoiesis exacerbates experimental insulin resistance in aging and obesity. Cell Rep 33(4):108326. https://doi.org/10.1016/j.celrep.2020.108326CrossRefPubMedPubMedCentral

27.

Bendtzen K, Mandrup-Poulsen T, Nerup J, Nielsen JH, Dinarello CA, Svenson M (1986) Cytotoxicity of human pI 7 interleukin-1 for pancreatic islets of Langerhans. Science 232(4757):1545–1547. https://doi.org/10.1126/science.3086977CrossRefPubMed

28.

Boni-Schnetzler M, Mereau H, Rachid L et al (2021) IL-1beta promotes the age-associated decline of beta cell function. iScience 24(11):103250. https://doi.org/10.1016/j.isci.2021.103250CrossRefPubMedPubMedCentral

29.

Maedler K, Sergeev P, Ris F et al (2002) Glucose-induced beta cell production of IL-1beta contributes to glucotoxicity in human pancreatic islets. J Clin Invest 110(6):851–860. https://doi.org/10.1172/JCI15318CrossRefPubMedPubMedCentral

30.

Jaiswal S, Natarajan P, Silver AJ et al (2017) Clonal hematopoiesis and risk of atherosclerotic cardiovascular disease. N Engl J Med 377(2):111–121. https://doi.org/10.1056/NEJMoa1701719CrossRefPubMedPubMedCentral

31.

Zekavat SM, Viana-Huete V, Matesanz N et al (2023) TP53-mediated clonal hematopoiesis confers increased risk for incident atherosclerotic disease. Nat Cardiovasc Res 2(2):144–158. https://doi.org/10.1038/s44161-022-00206-6CrossRefPubMedPubMedCentral

32.

Bhattacharya R, Zekavat SM, Haessler J et al (2022) Clonal hematopoiesis is associated with higher risk of stroke. Stroke 53(3):788–797. https://doi.org/10.1161/STROKEAHA.121.037388CrossRefPubMed

33.

Dorsheimer L, Assmus B, Rasper T et al (2019) Association of mutations contributing to clonal hematopoiesis with prognosis in chronic ischemic heart failure. JAMA Cardiol 4(1):25–33. https://doi.org/10.1001/jamacardio.2018.3965CrossRefPubMed

34.

Yu B, Roberts MB, Raffield LM et al (2021) Supplemental association of clonal hematopoiesis with incident heart failure. J Am Coll Cardiol 78(1):42–52. https://doi.org/10.1016/j.jacc.2021.04.085CrossRefPubMedPubMedCentral

35.

Shi C, Aboumsallem JP, Suthahar N et al (2023) Clonal haematopoiesis of indeterminate potential: associations with heart failure incidence, clinical parameters and biomarkers. Eur J Heart Fail 25(1):4–13. https://doi.org/10.1002/ejhf.2715CrossRefPubMed

36.

Tall AR, Fuster JJ (2022) Clonal hematopoiesis in cardiovascular disease and therapeutic implications. Nat Cardiovasc Res 1(2):116–124. https://doi.org/10.1038/s44161-021-00015-3CrossRefPubMedPubMedCentral

37.

Sano S, Oshima K, Wang Y et al (2018) Tet2-mediated clonal hematopoiesis accelerates heart failure through a mechanism involving the IL-1beta/NLRP3 inflammasome. J Am Coll Cardiol 71(8):875–886. https://doi.org/10.1016/j.jacc.2017.12.037CrossRefPubMedPubMedCentral

38.

Fuster JJ, MacLauchlan S, Zuriaga MA et al (2017) Clonal hematopoiesis associated with TET2 deficiency accelerates atherosclerosis development in mice. Science 355(6327):842–847. https://doi.org/10.1126/science.aag1381CrossRefPubMedPubMedCentral

39.

Yalcinkaya M, Liu W, Thomas LA et al (2023) BRCC3-mediated NLRP3 deubiquitylation promotes inflammasome activation and atherosclerosis in Tet2 clonal hematopoiesis. Circulation 148(22):1764–1777. https://doi.org/10.1161/CIRCULATIONAHA.123.065344CrossRefPubMedPubMedCentral

40.

Sato N, Goyama S, Chang YH et al (2024) Clonal hematopoiesis-related mutant ASXL1 promotes atherosclerosis in mice via dysregulated innate immunity. Nat Cardiovasc Res 3(12):1568–1583. https://doi.org/10.1038/s44161-024-00579-wCrossRefPubMed

41.

Fidler TP, Xue C, Yalcinkaya M et al (2021) The AIM2 inflammasome exacerbates atherosclerosis in clonal haematopoiesis. Nature 592(7853):296–301. https://doi.org/10.1038/s41586-021-03341-5CrossRefPubMedPubMedCentral

42.

Rauch PJ, Gopakumar J, Silver AJ et al (2023) Loss-of-function mutations in Dnmt3a and Tet2 lead to accelerated atherosclerosis and concordant macrophage phenotypes. Nat Cardiovasc Res 2(9):805–818. https://doi.org/10.1038/s44161-023-00326-7CrossRefPubMed

43.

Dawoud AAZ, Gilbert RD, Tapper WJ, Cross NCP (2022) Clonal myelopoiesis promotes adverse outcomes in chronic kidney disease. Leukemia 36(2):507–515. https://doi.org/10.1038/s41375-021-01382-3CrossRefPubMed

44.

Vlasschaert C, McNaughton AJM, Chong M et al (2022) Association of clonal hematopoiesis of indeterminate potential with worse kidney function and anemia in two cohorts of patients with advanced chronic kidney disease. J Am Soc Nephrol 33(5):985–995. https://doi.org/10.1681/ASN.2021060774CrossRefPubMedPubMedCentral

45.

Vlasschaert C, Robinson-Cohen C, Chen J et al (2024) Clonal hematopoiesis of indeterminate potential is associated with acute kidney injury. Nat Med 30(3):810–817. https://doi.org/10.1038/s41591-024-02854-6CrossRefPubMedPubMedCentral

46.

Kestenbaum B, Bick AG, Vlasschaert C et al (2023) Clonal hematopoiesis of indeterminate potential and kidney function decline in the general population. Am J Kidney Dis 81(3):329–335. https://doi.org/10.1053/j.ajkd.2022.08.014CrossRefPubMed

47.

Vlasschaert C, Lanktree MB, Rauh MJ, Kelly TN, Natarajan P (2024) Clonal haematopoiesis, ageing and kidney disease. Nat Rev Nephrol 20(3):161–174. https://doi.org/10.1038/s41581-023-00778-xCrossRefPubMed

48.

Vlasschaert C, Pan Y, Chen J et al (2024) Clonal hematopoiesis of indeterminate potential contributes to accelerated chronic kidney disease progression. medRxiv: 2024.2006.2019.24309181. https://doi.org/10.1101/2024.06.19.24309181

49.

Wei J, Yu Y, Wu H, Li Y, Wang N, Tan X (2025) Clonal haematopoiesis of indeterminate potential and risk of microvascular complications among individuals with type 2 diabetes: a cohort study. Diabetes. https://doi.org/10.2337/db24-0841CrossRefPubMed

50.

Denicolo S, Vogi V, Keller F et al (2022) Clonal hematopoiesis of indeterminate potential and diabetic kidney disease: a nested case-control study. Kidney Int Rep 7(4):876–888. https://doi.org/10.1016/j.ekir.2022.01.1064CrossRefPubMedPubMedCentral

51.

Wong WJ, Emdin C, Bick AG et al (2023) Clonal haematopoiesis and risk of chronic liver disease. Nature 616(7958):747–754. https://doi.org/10.1038/s41586-023-05857-4CrossRefPubMedPubMedCentral

52.

Andersson-Assarsson JC, van Deuren RC, Kristensson FM et al (2023) Evolution of age-related mutation-driven clonal haematopoiesis over 20 years is associated with metabolic dysfunction in obesity. EBioMedicine 92:104621. https://doi.org/10.1016/j.ebiom.2023.104621CrossRefPubMedPubMedCentral

53.

Pasupuleti SK, Ramdas B, Burns SS et al (2023) Obesity-induced inflammation exacerbates clonal hematopoiesis. J Clin Invest 133(11):e163968. https://doi.org/10.1172/JCI163968CrossRefPubMedPubMedCentral

54.

Uddin MM, Saadatagah S, Niroula A et al (2024) Long-term longitudinal analysis of 4,187 participants reveals insights into determinants of clonal hematopoiesis. Nat Commun 15(1):7858. https://doi.org/10.1038/s41467-024-52302-9CrossRefPubMedPubMedCentral

55.

Bolton KL, Zehir A, Ptashkin RN et al (2020) The clinical management of clonal hematopoiesis: creation of a clonal hematopoiesis clinic. Hematol Oncol Clin North Am 34(2):357–367. https://doi.org/10.1016/j.hoc.2019.11.006CrossRefPubMed

56.

Cavelti-Weder C, Babians-Brunner A, Keller C et al (2012) Effects of gevokizumab on glycemia and inflammatory markers in type 2 diabetes. Diabetes Care 35(8):1654–1662. https://doi.org/10.2337/dc11-2219CrossRefPubMedPubMedCentral

57.

Everett BM, Donath MY, Pradhan AD et al (2018) Anti-inflammatory therapy with canakinumab for the prevention and management of diabetes. J Am Coll Cardiol 71(21):2392–2401. https://doi.org/10.1016/j.jacc.2018.03.002CrossRefPubMed

58.

Kataria Y, Ellervik C, Mandrup-Poulsen T (2019) Treatment of type 2 diabetes by targeting interleukin-1: a meta-analysis of 2921 patients. Semin Immunopathol 41(4):413–425. https://doi.org/10.1007/s00281-019-00743-6CrossRefPubMed

59.

Meier DT, de Paula Souza J, Donath MY (2025) Targeting the NLRP3 inflammasome-IL-1beta pathway in type 2 diabetes and obesity. Diabetologia 68(1):3–16. https://doi.org/10.1007/s00125-024-06306-1CrossRefPubMed

60.

Larsen CM, Faulenbach M, Vaag A et al (2007) Interleukin-1-receptor antagonist in type 2 diabetes mellitus. N Engl J Med 356(15):1517–1526. https://doi.org/10.1056/NEJMoa065213CrossRefPubMed

61.

Ruscitti P, Masedu F, Alvaro S et al (2019) Anti-interleukin-1 treatment in patients with rheumatoid arthritis and type 2 diabetes (TRACK): a multicentre, open-label, randomised controlled trial. PLoS Med 16(9):e1002901. https://doi.org/10.1371/journal.pmed.1002901CrossRefPubMedPubMedCentral

62.

Sharma A, Choi JSY, Stefanovic N et al (2021) Specific NLRP3 inhibition protects against diabetes-associated atherosclerosis. Diabetes 70(3):772–787. https://doi.org/10.2337/db20-0357CrossRefPubMed

63.

Svensson EC, Madar A, Campbell CD et al (2022) TET2-driven clonal hematopoiesis and response to canakinumab: an exploratory analysis of the CANTOS randomized clinical trial. JAMA Cardiol 7(5):521–528. https://doi.org/10.1001/jamacardio.2022.0386CrossRefPubMedPubMedCentral

64.

Zuriaga MA, Yu Z, Matesanz N et al (2024) Colchicine prevents accelerated atherosclerosis in TET2-mutant clonal haematopoiesis. Eur Heart J 45(43):4601–4615. https://doi.org/10.1093/eurheartj/ehae546CrossRefPubMedPubMedCentral

65.

Chu CC, Chen YC, Lin MH et al (2022) Association between clinical use of colchicine and risk of type 2 diabetes mellitus among gouty patients: a nationwide cohort study. Int J Environ Res Public Health 19(6):3395. https://doi.org/10.3390/ijerph19063395CrossRefPubMedPubMedCentral

66.

Wang L, Sawhney M, Zhao Y, Carpio GR, Fonseca V, Shi L (2015) Association between colchicine and risk of diabetes among the veterans affairs population with gout. Clin Ther 37(6):1206–1215. https://doi.org/10.1016/j.clinthera.2015.03.010CrossRefPubMed

67.

Mohammadnia N, Los J, Opstal TSJ et al (2023) Colchicine and diabetes in patients with chronic coronary artery disease: insights from the LoDoCo2 randomized controlled trial. Front Cardiovasc Med 10:1244529. https://doi.org/10.3389/fcvm.2023.1244529CrossRefPubMedPubMedCentral

68.

Weinstock JS, Gopakumar J, Burugula BB et al (2023) Aberrant activation of TCL1A promotes stem cell expansion in clonal haematopoiesis. Nature 616(7958):755–763. https://doi.org/10.1038/s41586-023-05806-1CrossRefPubMedPubMedCentral

Title: Clonal haematopoiesis of indeterminate potential: an emerging risk factor for type 2 diabetes and related complications
Authors: María A. Zuriaga
José J. Fuster
Publication date: 10-03-2025
Publisher: Springer Berlin Heidelberg
Keywords: Type 2 Diabetes
Insulins
Insulins
Published in: Diabetologia
Print ISSN: 0012-186X
Electronic ISSN: 1432-0428
DOI: https://doi.org/10.1007/s00125-025-06393-8

Elevate your expertise in aplastic anemia (Link opens in a new window)

Aplastic Anemia
Independent Medical Education

Transform the way you care for your patients with aplastic anemia with our 3-module series using real-world case studies and expert insights. Discover why early diagnosis matters, explore the benefits and risks of current treatments, and develop tailored approaches for complex cases.

Supported by:

Pfizer

Developed by: Springer Healthcare IME

Learn more

Keynote series | Spotlight on menopause

Menopause
Video Series

Menopause can have a significant impact on the body, with effects ranging beyond the endocrine and reproductive systems. Learn about the systemic effects of menopause, so you can help patients in your clinics through the transition.

Prof. Martha Hickey

Dr. Claudia Barth

Dr. Samar El Khoudary

Developed by: Springer Medicine

Watch now

Podcast | Sexual health in older age

Springer Medicine

Abstract

Graphical Abstract

Please log in to get access to this content

Elevate your expertise in aplastic anemia (Link opens in a new window)

Keynote series | Spotlight on menopause